2 UH scientists receive prestigious national recognition for fostering innovation

top of the class

Mark Clarke (left) and Wei-Chuan Shih were named among the National Academy of Inventors' inaugural class of senior members. Courtesy of the University of Houston

Two researchers at the University of Houston have been named to the inaugural class of senior members for the National Academy of Inventors. The new distinction recognizes the honorees for fostering innovation and educating and mentoring future innovators — as well as their contribution to science and technology.

The two UH honorees are Mark Clarke, associate provost for faculty development and faculty affairs, and Wei-Chuan Shih, associate professor of electrical and computer engineering. Both will be recognized at the eighth annual NAI meeting in Houston this April, a release from UH says.

"Dr. Clarke and Dr. Shih both have impressive records of producing impactful intellectual property and spurring innovation that is pertinent to the Houston region," Amr Elnashai, vice president of research and technology at UH, says in the release. "Their further efforts, including helping UH faculty commercialize technologies as well as working with graduate and undergraduate students to boost their entrepreneurial efforts, are a critical contribution to building the region's innovation ecosystem."

NAI named 65 total scientists from 37 universities as senior members. The scientists have been named on over 1,100 patents issued in the United States. Ten other Texas scientists made the inaugural class, representing Texas Tech university, Texas A&M University, Baylor College of Medicine, and University of Texas at Arlington.

The organization also has a fellowship program, in which UH has 12 current fellows.

Clarke has been at UH for over a decade and previously held the position of associate vice chancellor/vice president for technology transfer at the UH Division of Research, where he oversaw a portfolio of 360 technology patents, according to the release. Clarke has 13 patents to his name and previously worked at two startups — both commercialized technologies Clarke developed in his tenure at NASA then UH.

UH's other senior NIA member, Shih, has been granted 11 patents in the US. His NanoBioPhotonics Group has developed a number of sensing and imaging technologies and devices for biomedicine and environmental testing, among other fields. Shih, who has been at the university for over nine years, created a startup with a group of students called DotLens. The company produced and distributed lenses that could be used to convert a smartphone into a microphone.

A few months ago, a Houston scientist received international recognition when he

won the Nobel Prize for the cancer research he did for the University of Texas MD Anderson Cancer center. Jim Allison won for his work in launching an effective new way to attack cancer by treating the immune system rather than the tumor.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice researchers score $45M from NIH for cancer-fighting tech

freshly funded

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

TMC again expands global impact with new Netherlands partnership

breaking news

The Texas Medical Center may be based in Houston, but the organization has again grown its global impact.

Since 2016, TMC’s BioBridges have worked with 88 startup companies. Those include strategic alliances with four other countries. Australia, the United Kingdom, Denmark and Ireland are all among TMC’s BioBridges partners. As of today, add the Netherlands to that list.

On September 27, TMC president and CEO, William F. McKeon, and Carmen van Vilsteren, chair of Health~Holland, Top Sector Life Sciences & Health (LSH), signed an agreement in Rotterdam. The TMC Netherlands BioBridge Memorandum of Understanding codifies the innovative goals of the partnership. Essentially, the BioBridge program provides a means for entrepreneurs, researchers, clinicians and industry partners from other countries to access the US market, as well as TMC experts.

“The TMC Netherlands BioBridge represents an unparalleled opportunity for collaboration and growth,” Ashley McPhail, chief external affairs & administration officer at Texas Medical Center said in a press release. “The Netherlands has solidified its position as a global leader in the field of life sciences and health, with a thriving ecosystem of research institutions, innovative companies, and highly skilled professionals. This strategic partnership will bring positive benefits to patients, clinicians and industry partners on a global scale.”

This lifeline for international healthcare companies makes expansion into the United States far smoother. The Global Innovators Launch Pad allows for startup founders to take part in a 10-week residency at the TMC Innovation Factory that will teach them about foundational infrastructure, clinical evidence and funding in the US.

“Since Texas is an important hub for innovation in the MedTech and digital health sectors, the collaboration with Texas Medical Center creates opportunities for Dutch companies looking to expand their international reach. Vice versa, it gives companies in Texas access to the vibrant Dutch Life Sciences & Health sector,” said van Vilsteren.

That exchange includes members of the TMC gaining the opportunity to participate in the Health~Holland Visitors Programme (HVP), “Shaping the Healthcare of the Future.”

The annual event invites high-level representatives from the private sector, NGOs, knowledge institutions, healthcare providers and different tiers of government to share their expertise.

It's the fifth partnership of its kind for TMC, with the last one being with Ireland, announced last year. TMC's other global initiatives include accelerators with Denmark and the United Kingdom, both announced earlier this year.

Houston startup founders prepare to scale globally following Shark Tank success

HOUSTON INNOVATORS PODCAST EPISODE 205

While Milkify's founders — husband and wife team Pedro Silva and Berkley Luck — secured partners on a popular business pitch and investment show, the entire experience almost didn't happen.

Silva and Luck, who got her PhD in molecular and biomedical s at Baylor College of Medicine, founded the company to provide breast milk freeze drying as a service to Houston-area families. Now, Milkify has customers across the country, but the duo didn't know if going through the process would be worth the investment and publicity, or if it would just be a distraction.

"The competitor in me wanted to be the first breast milk company to go on the show and to tell our story to the world — to show the world what my wife came up with that we thought was so great," Silva says on the Houston Innovators Podcast. "It was probably the scariest 45 minutes of my life."

But the sharks bit. Milkify's episode aired in April, and two investors — Gwyneth Paltrow and Lori Greiner — agreed to a $400,000 convertible note for 20 percent equity in the company. Paltrow even said on the show that she would have used the service when she was breastfeeding.

"It was empowering," Luck says of getting to wear her white coat on TV and share the story of how she came up with the idea of Milkify. "It was important to me when we went on the show to express that this had a scientific basis, that we didn't start this lightly, and that we've made huge strides in doing this in the absolute safest way possible."

Silva says they can't talk about some of the details of the show or the deal, but since then, Milkify has reached new customers, received additional investment interest, grown its team, and built out its plan to scale, the founders shared on the podcast. The team also shares its big-picture scale plans, which include tapping international partners to potentially take Milkify's tech global.

"Our vision is for every family to have access to breast milk formula, but instead of re-creating breast milk in a lab, we're doing it with mom's own milk," Silva says, mentioning a partnership with a breast milk bank that will convert its operation from freezing to freeze drying donated milk. "We're also working with groups in the UK and Australia to launch similar services using our patented technology."

"By the end of the year, we hope to see some announcements with those partnerships across the globe."

From the beginning, the importance of Milkify's team has been on supporting working parents to give them the best way to care for their families, Silva says. And for Luck — who says she's proud of the integrity Milkify has at its core despite competitors offering lower-quality and, in some cases, dangerous alternatives — she sees a lot of research benefits for the company.

"It's amazing to be at this leading edge, not just of innovation but of research, and to be able to still put out meaningful advances as an industry partner, not just as an academic," Luck says, adding that she hopes to be able to continue to contribute to the ongoing research into breast milk.

Luck and Silva share more about their Shark Tank experience, their co-founder strengths, and the future of Milkify on the podcast. Listen to the interview here — or wherever you stream your podcasts — and subscribe for weekly episodes.

View All Listings